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Therapeutics drugs cover was good compared to previous studies: 98% of
patients has been treated by beta blockers, 94% by an antagonist of renin-
angiotensin-aldosteron system and 82% by an antagonist of mineralocorticoid
receptor. Survival after 3 years of treatment was 87.5%. Re-admission rate
was less than one readmission per patient and per year. No diagnosis param-
eter was a prognosis factor. But after 6 months of treatment, univariate anal-
ysis found significant prognosis factors of survival: dyspnea I-II, 6 minutes
walking test >300m, BNP<400ng/ml (p<0,001). In multivariate analysis only
BNP<400ng/ml at 6 months was associated with survival (p=0,012).
Conclusion Heart failure management unit in Bordeaux is conformed to
European guidelines. Ambulatory sector is a good solution to cope with
increasing activity. The most predictive factor of survival in our unit experi-
ence was evaluation at 6 months after diagnosis (like BNP<400ng/ml).
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Introduction Controversial results have been published concerning a pos-
sible gender survival difference in patients with chronic heart failure (CHF).
Methods We analyzed data from consecutive patients with stable CHF
admitted to our chronic heart failure unit. Patients underwent coronary angi-
ography, echocardiography and biological exams.
Results We included 563 consecutive patients of whom 243 (43.16%) were
women. The major difference in clinical characteristics was a higher propor-
tion of hypertension, dyslipidemia and diabetes in women compared to men
(64.9 vs. 35.1%; p=0.01, 65.9% vs. 34.1%; p=0.0001 and 62.7% vs. 37.3%;
p=0.0001 respectively), men are more frequently smoker with higher ischemic
cardiomyopathy compared to women (64.6% vs. 35.4%, p=0.0001), they had
a lower left ventricular ejection fraction (35%±9 vs. 38%±9%, p=0.05). Level
of serum uric acid was higher in men (63.7±18.1 g/l vs. 59.1±20.3 g/l;
p=0.005) while they preserved more their mean Glomerular Filtration Rate
(GFR): 65.17±24.6mL/min vs. 58.47±22.98mL/min. Therapeutic management
was similar in men and women. There was no gender difference in cardiac
survival. Cardiovascular mortality rates at 2 years were 11% in men and 13%
in women.
Conclusions Despite a lower percentage of ischemic cardiomyopathy in
women, no gender survival benefit was found in our population of CHF
patients receiving optimal medical therapy.
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Purpose FDG-positron emission tomography (PET) has high diagnostic
accuracy in cardiac sarcoidosis (CS). Beyond CS, the non invasive diagnosis
of inflammatory cardiomyopathies (IC) is challenged by a lower diagnostic
performance of usual tools as magnetic resonance imaging (MRI). 
Methods 17 consecutive patients with suspected IC had a FDG-PET to
detect myocardial inflammation. From all clinical data including PET, we
classified patients in either CS or non-CS and respective PET data were com-
pared. The clinical impact of adding PET in the non-CS group was evaluated
by comparing diagnosis and management proposed by an expert blind to PET
with final diagnosis and management actually held in practice. 
Results 6 patients had CS, all with positive PET. In the 11 non-CS
patients, 7 had a positive PET. All had MRI late gadolinium enhancement in
FDG uptake areas, suggesting a true positivity of PET for the presence of
inflammation. PET data were all significantly different between CS and non-
CS patients with positive PET, particularly the coefficient of variation of car-
diac SUV which is an index of heterogeneity of FDG uptake was significantly
greater in CS patients (0,4 vs 0,17 p<0,002). In non-CS patients, 2 were clas-
sified as certain IC, 2 as excluded IC, and 7 as possible IC by an expert blind
to PET. Adding PET in clinical practice, IC was excluded for 5 of the 7
patients with possible IC, 2 patients remained with a possible IC diagnosis and
the 2 certain IC were confirmed. PET did not change patient management in
terms of endomyocardial biopsy or immunosuppressive therapy. 
Conclusion Some patients with suspected IC had a positive FDG-PET in
favour of myocardial inflammation, with a different pattern from that observed
in CS. Adding PET to usual diagnostic tools led to a decrease of possible IC
diagnosis that turned in excluded IC. These preliminary data suggest a poten-
tial role of PET for the non-invasive diagnosis of IC that will need further
investigations.
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Introduction Antiphospholipid syndrome (APLS) is defined by the occur-
rence thrombosis, and/or obstetric morbidity associated with the presence of
antiphospholipid antibodies. Cardiovascular manifestations of APLS are vari-
able and some of them can be life threatening.
Patients and Methods Retrospective study of patients with APLS (diag-
nosed according to Sidney classification criteria of 2006) in an Internal medi-
cine department over a period of 14 years.
Results Thirty-four patients with APLS had cardiovascular involvements
(66.6%); 30 females and 4 males, with a mean age of 40.5 years (24-74 years).
Cardiovascular involvements revealed the disease in 53% of cases. Venous
thromboses were most frequent manifestation: deep-vein thrombosis (DVT)
(12 cases), pulmonary embolism (5 cases), cerebral venous thrombosis
(1 case), inferior vena cava thrombosis (1 case), portal vein thrombosis
(1 case), superficial venous thrombosis (1 case) and central retinal vein occlu-
sion (2 cases). Arterial thromboses were noted in 12 patients: stroke (9 cases),
upper limb artery, renal artery and occlusion of central retinal artery (each in
1 patient). Acute coronary artery thrombosis was observed in one patient
(myocardial infarction). Pericarditis was noted in 3 cases, valvular disease in
2 cases (an aortic and a mitral stenosis), and myocarditis in 1 patient. Anti-
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